Melanoma antigen recognized by T cells 1 (MART-1) (MART-1)

Melanoma antigen recognized by T cells 1 (MART-1), also known as Melan-A, is a lineage-specific differentiation antigen primarily expressed in melanocytes and the majority of melanoma cells [3, 11]. It is a transmembrane protein localized to melanosomes, where it plays a critical role in the biogenesis of these organelles and the synthesis of melanin [4]. In clinical oncology, MART-1 serves as a prominent tumor-associated antigen (TAA) for the development of immunotherapies, particularly for metastatic and uveal melanoma [6, 11]. These therapies, which include TCR-engineered T cells and peptide-based vaccines, aim to stimulate or redirect cytotoxic T lymphocytes (CTLs) to recognize MART-1 peptide fragments presented by MHC Class I molecules, specifically HLA-A*02:01 [7, 13]. While highly effective at targeting melanoma, these treatments can cause significant 'on-target, off-tumor' toxicities due to the presence of normal melanocytes in the skin, eyes, and inner ear [2]. This can lead to clinical conditions such as vitiligo, uveitis, and hearing loss, which represent major therapeutic challenges in the clinical application of MART-1-targeted agents [2, 6].

Other names

Melan-AMLANAAntigen LB39-AAAntigen SK29-AAProtein Melan-A

T-cell receptor (TCR) recognition of MART-1 peptide fragments presented by HLA-A*02:01 on the cell surface, triggering cytotoxic T-lymphocyte activation and tumor cell lysis [7, 13].